Adrian L Harris
MB.ChB, BSc Hons, MA, DPhil, MD [Hon], FRCP, FMedSci, DSc[Med]
Emeritus Professor of Medical Oncology
- Professorial Fellow, St Hugh's College
- Consultant Medical Oncologist, Oxford University Hospitals NHS Trust
Biography
From 1989-2017, Adrian L Harris was the first Professor of Medical Oncology at Oxford University and developed the Department. He has been Cancer Research UK Professor of Medical Oncology at the University of Oxford since 1989 and directed the Cancer Research UK Molecular Oncology Laboratories at the Weatherall Institute of Molecular Medicine (WIMM) until 2017. He was a Consultant Medical Oncologist and is a Professorial Fellow of St Hugh’s College Oxford. Prof. Harris was Editor-in-Chief of the British Journal of Cancer for 15 years, and on the Editorial Board of Cancer Cell. He is a Senior Investigator in the National Institute of Health Research and a founder Fellow of the Academy of Medical Sciences. He was a Trustee and Chairman of the Science Strategy Committee for Breast Cancer NOW.
Prof. Harris is a ‘Highly Cited Researcher’, ranking among the top 1% most cited for their subject field and year of publication. He has published over 500 articles and there are over 196,000 citations to them, Google Scholar h index 213.
Prof. Harris received a Platinum Merit Award from the National Health Service for the last 15 years, given to the 200 most outstanding consultants for all specialities.
Prof. Harris trained in Medicine and Biochemistry at Liverpool University, did a DPhil at Oxford University then trained at the Royal Marsden Hospital in Medical Oncology. He was appointed Professor of Clinical Oncology at Newcastle-upon-Tyne in 1982. He has managed breast cancer patients for over 35 years. He continues run research programmes in Oxford University.
His major laboratory interests involve the role of hypoxia in breast tumour biology, tumour angiogenesis, the metabolic response to hypoxia, and hypoxia-induced cell death. He has conducted many predictive and prognostic studies and early exploratory phase trials in new drug development. He used molecular pathology and biomarkers to develop new agents with pharmacodynamic monitoring for proof of target engagement.
Key publications
-
Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis.
Journal article
Dragovic RA. et al, (2011), Nanomedicine, 7, 780 - 788
-
Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma.
Journal article
Lawrie CH. et al, (2008), Br J Haematol, 141, 672 - 675
-
Breast cancer classification and prognosis based on gene expression profiles from a population-based study.
Journal article
Sotiriou C. et al, (2003), Proc Natl Acad Sci U S A, 100, 10393 - 10398
-
Hypoxia--a key regulatory factor in tumour growth.
Journal article
Harris AL., (2002), Nat Rev Cancer, 2, 38 - 47
-
Hypoxia-inducible expression of tumor-associated carbonic anhydrases.
Journal article
Wykoff CC. et al, (2000), Cancer Res, 60, 7075 - 7083
-
The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages.
Journal article
Talks KL. et al, (2000), Am J Pathol, 157, 411 - 421
-
Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma.
Journal article
Leek RD. et al, (1996), Cancer Res, 56, 4625 - 4629

